Long-term use of non-steroidal anti-inflammatory drugs in the treatment of axial spondylitis
- Authors: Erdes S.F1, Rumiantceva D.G.1
-
Affiliations:
- V.A. Nasonova Research Institute of Rheumatology
- Issue: Vol 26, No 13 (2019)
- Pages: 24-29
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312377
- DOI: https://doi.org/10.18565/pharmateca.2019.13.24-29
- ID: 312377
Cite item
Abstract
The article presents relevant data on the main principles and recommendations for the management and treatment of patients with axial spondyloarthritis (axSpA). Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line drugs prescribed for axSpA. The effect of NSAIDs on the activity and radiological progression of axSpA is described in detail. From the perspective of a balance of efficacy and safety profile of NSAIDs, patients with axSpA can use selective COX-2 inhibitor etoricoxib (Arcoxia®) for a long time; it has been well studied with prolonged use and has a large base of research with a high degree of evidence.
Full Text
About the authors
Sh. F Erdes
V.A. Nasonova Research Institute of RheumatologyLaboratory of Spondyloarthritis and Psoriatic Arthritis
Daria G. Rumiantceva
V.A. Nasonova Research Institute of Rheumatology
Email: rumiantceva01@gmail.com
PhD, Junior Reseracher at the Laboratory of Spondyloarthritis and Psoriatic Arthritis
References
- Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr OpinRheumatol. 2010;22(4):375-80. Doi: 10.1097/ bor.0b013e32833ac5cc
- Подряднова М.В., Балабанова РМ., Урумова М.М., Эрдес Ш.Ф. Взаимосвязь клинических характеристик анкилозирующего спондилита с трудоспособностью и производительностью труда. Научно-практическая ревматология. 2014;52(5):513-19. Doi: https://doi.org/10.14412/1995-4484-2014-513-519. Doi: https:// doi.org/10.14412/1995-4484-2014-513-519.
- Smolen J.S., Schols M., Braun J., et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheumatic Dis. 2018;77:3-17. doi: 10.1136/annrheumdis-201 7-211734.
- Гайдукова И.З., Ребров А.П., Коротаева Т. В. и др. Ремиссия при аксиальных спондилоартритах - определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»). Научно-практическая ревматология. 2018;56(1):10-14. Doi: https://doi.org/10.14412/1995-4484-2018-10-14. Doi: https://doi. org/10.14412/1995-4484-2018-10-14.
- Van der Heijde D., Ramiro S., Landewe R., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases. 2017;76(6):978-91. Doi: https://doi. org/10.1136/annrheumdis-2016-210770.
- Гайдукова И.З., Ребров А.П., Лапшина С.А. и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научнопрактическая ревматология. 2017;55(5): 474-84.
- van der Heijde D., Baraf H.S., Ramos-Remus C., et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52:1205e15. doi: 10.1002/art.20985.
- Sari I., Ozturk M.A., Akkoc N. Treatment of ankylosing spondylitis. Turk J. Med Sci. 2015;45:416e30.
- Kroon F., Burg L., Ramiro S., et al. Non-steroidal anti-inflammatory drugs in axial spondyloarthritis: a Cochrane review. J. Rheumatol. 2014;43:607-17. Doi: http://dx.doi.org/10.3899/jrheum.150721.
- Wong R.S.Y. Disease-Modifying Effects of LongTerm and Continuous Use of Nonsteroidal AntiInflammatory Drugs (NSAIDs) in Spondyloarthritis. Advan Pharmacol Sci. 2019;2019. Doi: https:// doi.org/10.1155/2019/5324170
- Simon D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437. doi: 10.1124/pr.56.3.3.
- Warner T.D., Mitchel J.A. Cycloxygenase: new isoforms, new inhibitors, and new lessons from clinic. FASEB J. 2004;18:790-804.
- Rao P., Knaus E.E. Evolution of nonsteroidal antiinflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm Pharmaceut Sci. 2008;11(2):81-110.
- Sanchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A., Gonzalez-Aveledo L. Hypersensitivity reactions to nonsteroidal anti-Inflammatory drugs: an update. Pharmaceuticals. 2010;3(1):10-8. Doi: https://doi.org/10.3390/ph3010010.
- Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921 25. doi: 10.1136/ard.2011.151191
- Haroon N.N., Paterson J.M., Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163:409-16. doi: 10.7326/M14-2470.
- Wang R., Dasgupta A., Ward M.M. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016;75:1152-60. Doi: 10.1136/ annrheumdis-2015-207677.
- Sieper J., lenaerts J., Wollenhaupt J., et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axia spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73:101-7l.
- Kroon F, Burg L., Ramiro S., et al. Non-steroidal anti-inflammatory drugs in axial spondyloarthritis: a Cochrane review. J Rheumatol. 2014;43:607 17. Doi: http://dx.doi.org/10.3899/jrheum. 150721
- Tang M., et al. Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients. Clinil Rheumatol. 2018;37(1): 245-50.
- Wanders A, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis & Rheumatism. 2000;02(6):1706 60. doi: 10.1002/art.21004
- Kroon F., Landewe R., Dougados M., et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623-29. Doi: 10.1136/ annrheumdis-2012-201370.
- Poddubnyy D., Rudwaleit M., Haibel H., et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616-22. Doi: 10.3899/ jrheum.100721.
- Румянцева Д.Г., Дубинина Т. В., Эрдес Ш.Ф. Влияние частоты приема нестероидных противовоспалительных препаратов на рентгенологическое прогрессирование сакроилиита у пациентов с ранним аксиальным спондилоартритом. Научно-практическая ревматология. 2018;06(3):346-00.
- Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научнопрактическаяревматология. 2018;06:1-29. Doi: https://doi.org/10.14412/1990-4484-2018-1 29
- Sostres C., Gargallo C.J., Arroyo M.T., Lanas A. Adverse effects of non-steroidal antiinflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121-32. doi: 10.1016/j.bpg.2009.11.000.
- Kivitz A.J., Nayiager S., Schimansky T., et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Therapeut. 2004;19(11);1189-98. doi: 10.1111/j.1360-2036.2004.01906.x.
- Whittle B.J.R. The potentiation of taurocholate-induced rat gastric erosions following parenteral administration of cyclooxygenase inhibitors. Br J Pharmacol. 2012;80(3):040-01.
- Peskar B.M. Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. Inflammopharmacology. 2000;13(1-3):10-26.
- Каратеев А.Е. и др. Эндоскопическая картина верхних отделов желудочно-кишечного тракта на фоне приема различных НПВП. Клиническая фармакология и терапия. 2018;4.
- Fournier J.-P, Sommet A., Bourrel R., et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Eur J Clin Pharmacol. 2012;68:1033-40. Doi: 10.1007/ s00228-012-1283-9.
- John C.M., Shukla R., Jones C.A. Using NSAID in volume depleted children can precipitate acute renal failure. Arch Dis Childhood. 2007;92(6):024-26. doi: 10.1136/adc.2006.103064.
- Mackenzie I.S., MacDonald T.M. Treatment of osteoarthritis in hypertensive patients. Exp Opin Pharmacother. 2010;11(3):393-403.
- Harirforoosh S., Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Exp Opin Drug Saf. 2009;8(6):669-81. doi: 10.1017/14740330903311023.
- Zingler G., Hermann B., Fischer T., Herdegen T. Cardiovascular adverse events by nonsteroidal anti-inflammatory drugs: when the benefits outweigh the risk. Exp Rev Clin Pharmacol. 2016;9(11):1479-92. doi: 10.1080/17012433.2016.1230490.
- Harirforoosh S., Asghar W., Jamali F Adverse effects of nonsteroidal anti-inflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharmaceutl Sci. 2013;16(0):821-47.
- Whelton A. Nephrotoxicity of nonsteroidal antiinflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(2):13S-34S. doi: 10.1016/s0003-9343(99)00113-8.
- Dixit M., Nguyen C., Carson T., et al. Nonsteroidal antiinflammatory drugs-associated acute interstitial nephritis with granular tubular basement membrane deposits. Paediatr Nephrol. 300-;33()):)42-4-. doi: 10.1007/s00467-007-0080-0.